Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)

Trial Profile

Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms RESPONSE
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 12 Dec 2017 Long-term efficacy and safety results after a follow-up of 208 weeks, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 10 Dec 2017 Results presented in an Incyte corporation media release.
    • 10 Dec 2017 According to an Incyte corporation media release, new 208-week (4-year) follow-up data were shared in an oral presentation today at the 59th American Society of Hematology (ASH) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top